Liver Disease Therapeutic Market is expected to reach US$ 39.41 billion by 2034 from US$ 22.53 billion in 2025, with a CAGR of 6.41% from 2026 to 2034. Rising prevalence of chronic liver diseases, growing investment in RNA-based therapies, major acquisitions, and breakthrough-designated drug candidates are accelerating market growth. Expanding clinical pipelines and strategic partnerships continue to drive innovation in alcoholic hepatitis, NASH, and other advanced liver disorders.
A major growth driver for the Liver Disease Therapeutic Market is the surge in strategic collaborations and acquisitions aimed at accelerating next-generation treatments. In May 2024, Bausch Health acquired DURECT Corporation for USD 63 million, gaining larsucosterol - an FDA Breakthrough Therapy-designated candidate for alcoholic hepatitis with significant market potential. Simultaneously, rising liver disease prevalence and the shift toward RNA-based and regenerative approaches continue to attract investment. Pharmaceutical companies are expanding pipelines across NASH, alcoholic liver disease, and fibrosis, while regulatory incentives shorten development timelines. These trends collectively strengthen market growth and foster rapid advancement of novel liver therapeutics.
Liver Disease Therapeutic Industry Overview
The Liver Disease Therapeutic Market includes medications and advanced biologic or genetic therapies designed to treat conditions such as nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, cirrhosis, liver fibrosis, viral hepatitis, and rare metabolic disorders. Treatment approaches range from antiviral agents and anti-inflammatory drugs to RNA-based therapeutics, regenerative medicine, and metabolic pathway modulators. Market expansion is driven by the rising global burden of liver disease, aging populations, and lifestyle factors such as alcohol use and obesity. Increased investment by pharmaceutical companies, breakthrough regulatory designations, clinical trial advancements, and large-scale partnerships are accelerating development of targeted and disease-modifying liver therapies.A major growth driver for the Liver Disease Therapeutic Market is the surge in strategic collaborations and acquisitions aimed at accelerating next-generation treatments. In May 2024, Bausch Health acquired DURECT Corporation for USD 63 million, gaining larsucosterol - an FDA Breakthrough Therapy-designated candidate for alcoholic hepatitis with significant market potential. Simultaneously, rising liver disease prevalence and the shift toward RNA-based and regenerative approaches continue to attract investment. Pharmaceutical companies are expanding pipelines across NASH, alcoholic liver disease, and fibrosis, while regulatory incentives shorten development timelines. These trends collectively strengthen market growth and foster rapid advancement of novel liver therapeutics.
Growth Drivers for the Liver Disease Therapeutic Market
Strategic Acquisitions Strengthening Innovative Drug Pipelines
Acquisitions have become a critical engine for market momentum as major pharmaceutical companies seek promising liver disease assets. A prime example is Bausch Health’s USD 63 million acquisition of DURECT Corporation in May 2024. This deal granted Bausch access to larsucosterol, a novel candidate for alcoholic hepatitis that holds FDA Breakthrough Therapy Designation and carries a potential value of up to USD 413 million including future milestone payments. Alcohol-associated liver disease remains one of the fastest-growing global health burdens, with limited treatment options, making breakthrough-designated therapies highly valuable. Such acquisitions accelerate clinical development by providing companies with advanced R&D infrastructure, global commercialization networks, and regulatory expertise. By integrating emerging therapeutics into broader strategic portfolios, companies can rapidly scale innovation. This trend also increases competition, driving further investment across the industry. As more firms pursue high-impact assets, acquisitions will remain a major driver shaping the evolution of the liver disease therapeutic market.Multi-Billion-Dollar Collaborations in Regenerative and RNA-Based Therapies
Large-scale partnerships are propelling the next wave of liver disease innovation, particularly in regenerative medicine and RNA therapy. In April 2024, Boehringer Ingelheim entered a transformative collaboration with Ochre Bio valued at over USD 1 billion to develop regenerative treatments for advanced liver disease. Their joint focus on deep phenotyping, gene profiling, and RNA-based interventions aims to enhance the liver’s natural self-repair capacity - a significant leap from conventional anti-inflammatory drugs. These partnerships reflect rising demand for disease-modifying therapies that target cellular dysfunction rather than just symptoms. RNA therapeutics, including siRNA and mRNA platforms, enable precise modulation of pathogenic genes implicated in fibrosis, steatosis, and hepatocyte injury. As pharmaceutical leaders invest heavily in these modalities, the field is shifting toward durable solutions with the potential to reverse liver damage. Such large-scale collaborations dramatically accelerate research timelines, clinical validation, and market readiness, establishing regenerative and RNA-based technologies as central growth drivers.Expansion of RNA Interference (RNAi) Therapies in NASH and Fibrotic Liver Disorders
RNA interference is emerging as one of the most promising mechanisms for treating chronic liver diseases, including NASH and advanced fibrosis. In January 2024, Boehringer Ingelheim partnered with Suzhou Ribo Life Science in a deal potentially exceeding USD 2 billion to develop RNAi therapeutics targeting disease-associated genes in hepatocytes. By silencing pathogenic pathways responsible for inflammation, metabolic dysfunction, and fibrosis progression, RNAi therapies offer a highly targeted approach with long-lasting effects. The rising prevalence of NASH - driven by obesity, aging populations, and metabolic syndrome - creates significant demand for innovative treatments, as no FDA-approved therapy currently exists. Pharmaceutical companies are therefore aggressively expanding RNAi pipelines, leveraging improved delivery technologies and safer chemical modifications. These advancements, combined with major financial investments, enhance confidence in RNA-based solutions and accelerate clinical progress. As RNAi becomes increasingly integrated into liver disease treatment strategies, it stands as a major market growth catalyst.Challenges in the Liver Disease Therapeutic Market
Limited Approved Therapies and High Clinical Trial Failure Rates
Despite growing investment, liver disease therapeutics face significant challenges due to limited FDA-approved drugs for major conditions like NASH and alcoholic hepatitis. Many candidates targeting fibrosis, metabolism, or inflammation fail during late-stage clinical trials because liver diseases involve complex, multifactorial pathways. Variability in patient populations, difficulties in measuring disease progression, and stringent regulatory expectations add additional barriers. High trial costs and long development timelines also reduce the number of companies willing to pursue innovative therapies. These limitations slow overall market growth and delay the availability of urgently needed treatments. Addressing these issues requires improved biomarkers, better patient stratification, and more adaptive regulatory frameworks.High Treatment Costs and Uneven Global Access
Advanced liver disease therapies - including RNA-based therapeutics, biologics, and regenerative treatments - often come with high prices, making them inaccessible for many patients in low- and middle-income markets. Even in developed regions, reimbursement gaps can limit the use of novel treatments, especially those not yet supported by long-term data. High diagnostic costs, limited specialist availability, and inadequate screening infrastructure further restrict timely treatment. As liver diseases progress silently, many patients reach severe stages before receiving care, increasing financial burdens on healthcare systems. These economic and accessibility barriers hinder adoption and slow overall market expansion, despite significant therapeutic advancements.United States Liver Disease Therapeutic Market
The United States represents one of the most advanced and commercially significant liver disease therapeutic markets, driven by high prevalence of NASH, alcoholic liver disease, and hepatitis-related disorders. Strong investment in biotechnology, rapid adoption of RNA-based therapies, and robust clinical trial activity contribute to market growth. The U.S. regulatory environment, including Breakthrough Therapy and Fast Track designations, accelerates development for high-need conditions. Major companies actively expand pipelines through partnerships and acquisitions, reflecting strong demand for disease-modifying treatments. High healthcare expenditure and widespread access to diagnostic technologies further support therapeutic adoption. With a strong innovation ecosystem, the U.S. continues to lead the global liver disease treatment landscape.Germany Liver Disease Therapeutic Market
Germany’s market for liver disease therapeutics is supported by strong healthcare infrastructure, high diagnostic accuracy, and comprehensive reimbursement for advanced treatments. The country faces rising prevalence of fatty liver disease and alcohol-related conditions, driving demand for innovative therapies. German research institutions actively participate in clinical trials focused on fibrosis modulation, RNA therapeutics, and regenerative medicine. Collaboration between academic centers and global pharmaceutical companies accelerates therapeutic testing and early adoption. The market benefits from strong regulatory standards under the European Medicines Agency (EMA), ensuring safety and efficacy of emerging drugs. With increasing focus on precision medicine and chronic disease management, Germany remains a critical European hub for liver disease treatment growth.China Liver Disease Therapeutic Market
China is experiencing rapid growth in the liver disease therapeutic market due to high rates of viral hepatitis, fatty liver disease, and rising obesity levels. Government healthcare reforms and expansion of health insurance coverage have improved access to diagnostics and treatment. Domestic biopharmaceutical companies are increasingly investing in RNAi, biologics, and antifibrotic therapies, strengthening the competitive landscape. China also plays a significant role in global clinical trials, supported by a large patient population and accelerated regulatory pathways for innovative medicines. Growing healthcare spending, urbanization, and early screening initiatives further drive market expansion. As innovation increases, China continues to evolve as one of the fastest-growing markets for liver disease therapeutics.Saudi Arabia Liver Disease Therapeutic Market
Saudi Arabia’s liver disease therapeutic market is expanding due to high prevalence of metabolic disorders, including obesity, diabetes, and NASH. Healthcare transformation efforts under Vision 2030 are improving screening, diagnostics, and specialty treatment capacity. Investments in advanced hospitals and digital health infrastructure enhance early detection and disease management. The government is also increasing reimbursement for novel therapies, making innovative treatments more accessible. International pharmaceutical companies maintain a strong presence through partnerships with local distributors and healthcare providers. Continued public health campaigns promoting lifestyle changes and early diagnosis further support market growth. As chronic liver diseases rise, Saudi Arabia remains a key regional market for therapeutic advancement.Recent Developments in Liver Disease Therapeutic Market
- May 2025: GSK announced a USD 1.2 billion acquisition of efimosfermin from Boston Pharmaceuticals, expanding its liver disease portfolio with a next-generation FGF21 analog designed to address metabolic liver disorders.
- June 2025: AbbVie received FDA approval for a label expansion of MAVYRET (glecaprevir/pibrentasvir), making it the first and only pangenotypic DAA approved to treat acute HCV in just eight weeks with a 96% cure rate. The therapy is now indicated for adults and children aged three years and older, with or without compensated cirrhosis.
- March 2025: Takeda Pharmaceutical Company Limited secured approval from Japan’s Ministry of Health, Labour and Welfare for Livmarli (maralixibat) oral solution to treat Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), reinforcing its commitment to rare pediatric liver diseases with unmet therapeutic needs.
Liver Disease Therapeutic Market Segments
Therapy Type
- Anti-Rejection Drugs/Immunosuppressants
- Chemotherapy Drugs
- Targeted therapy
- Vaccines
- Immunoglobulins
- Corticosteroids
- Anti-Viral Drugs
Disease Type
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Viral Hepatitis (B, C, D)
- Alcoholic Liver Disease (ALD)
- Autoimmune Liver Disease (ALD)
End Users
- Hospitals
- Laboratories
- Others
Country
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- the Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
All the Key players have been covered from 5 Viewpoints:
- Overview
- Key Person
- Product Analysis
- Recent Development
- Revenue
Company Analysis
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Mayers Squibb
- Gilead Sciences
- GlaxoSmithKline Pharmaceuticals Ltd
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceuticals
Table of Contents
1. Introduction3. Executive Summary
2. Research & Methodology
4. Market Dynamics
5. Global Liver Disease Therapeutic Market
6. Market Share Analysis
7. Therapy Type
8. Disease Type
9. End Users
10. Countries
11. Porter's Five Forces Analysis
12. SWOT Analysis
13. Market Outlook and Opportunities
14. Key Players Analysis
Companies Mentioned
- Abbott Laboratories
- Astellas Pharma Inc.
- Bristol-Mayers Squibb
- Gilead Sciences
- GlaxoSmithKline Pharmaceuticals Ltd
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceuticals
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 22.53 Billion |
| Forecasted Market Value ( USD | $ 39.41 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
